Exploring the Quality of Communication Between Patients with Psoriatic Arthritis and Physicians: Results of a Global Online Survey.

Communication Health-related quality of life Patients Physicians Psoriatic arthritis Surveys and questionnaires

Journal

Rheumatology and therapy
ISSN: 2198-6576
Titre abrégé: Rheumatol Ther
Pays: England
ID NLM: 101674543

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 25 05 2021
accepted: 26 08 2021
pubmed: 28 9 2021
medline: 28 9 2021
entrez: 27 9 2021
Statut: ppublish

Résumé

Effective communication between patients with psoriatic arthritis (PsA) and their physicians is important for optimizing treatment outcomes. We assessed the quality of patient-physician communication in terms of awareness and impact of PsA symptoms, their levels of satisfaction, and their perceptions of communications. A global online survey was conducted by The Harris Poll in adult patients with PsA and physicians managing patients with PsA in eight countries. Participating physicians were either rheumatologists or dermatologists seeing ≥ 10 and ≥ 5 patients with PsA per month, respectively. Patient and physician groups were unmatched. Patient-physician communication was assessed with 35-60 questions regarding discussion topics during consultations, levels of satisfaction with communication, and specific communication issues. A total of 1286 patients with PsA (983 and 303 whose primary treating physician was a rheumatologist or dermatologist, respectively) and 1553 physicians (795 rheumatologists and 758 dermatologists) completed the survey. Regardless of whether they were primarily treated by a rheumatologist or dermatologist, most patients reported a social (84% and 81%, respectively) or work (81% and 80%, respectively) impact of PsA, and a major/moderate negative impact on their physical activity levels (79% and 74%, respectively) or emotional/mental wellbeing (69% and 68%, respectively). Physician responses were generally consistent with this; however, physicians often appeared to under-recognize the extent to which PsA affects patients. Most (≥ 85%) patients and physicians were very/somewhat satisfied with their patient-physician communication, and most (≥ 86%) patients were comfortable raising their concerns/fears with their physician. However, > 40% of patients were identified as being at risk of suboptimal communication. These patients were significantly less likely to report their PsA symptoms even when asked, were less comfortable discussing the impacts of PsA with their physician, and were more likely to experience major/moderate impacts of PsA on their health-related quality of life (HRQoL). Physicians often underestimate the impacts of PsA, compared with patients, and some patients may be at risk of suboptimal communication with their attending physician, which may worsen the HRQoL impacts of PsA. These findings highlight a need for ways to improve communication between patients with PsA and their healthcare providers. Psoriatic arthritis (PsA) is a disease that can cause swollen and painful joints, as well as skin psoriasis. To effectively treat PsA, it is important that doctors and patients communicate well. We used a survey to ask patients with PsA and doctors from around the world about their communications about PsA. We also asked how PsA affects patients’ quality of life. In total, 1286 patients and 1553 doctors took the survey. Most patients said that PsA affected their social and work lives. Similarly, PsA had a negative impact on physical activity and on emotional and/or mental wellbeing in most patients who answered the survey. Doctors answered similarly, but they were generally less likely to recognize how severely PsA can impact patients, compared with patients themselves. Most patients and doctors were happy with their patient–doctor communication, and most patients felt comfortable talking about their worries and/or fears with their doctor. However, some patients (about four out of 10) felt that communication with their doctors was not good; these patients were less likely/comfortable to talk about their PsA symptoms and the impacts of PsA with their doctor. PsA was also more likely to negatively impact these patients’ quality of life. This survey shows that it is important to find ways to improve communication between patients with PsA and their doctors.

Autres résumés

Type: plain-language-summary (eng)
Psoriatic arthritis (PsA) is a disease that can cause swollen and painful joints, as well as skin psoriasis. To effectively treat PsA, it is important that doctors and patients communicate well. We used a survey to ask patients with PsA and doctors from around the world about their communications about PsA. We also asked how PsA affects patients’ quality of life. In total, 1286 patients and 1553 doctors took the survey. Most patients said that PsA affected their social and work lives. Similarly, PsA had a negative impact on physical activity and on emotional and/or mental wellbeing in most patients who answered the survey. Doctors answered similarly, but they were generally less likely to recognize how severely PsA can impact patients, compared with patients themselves. Most patients and doctors were happy with their patient–doctor communication, and most patients felt comfortable talking about their worries and/or fears with their doctor. However, some patients (about four out of 10) felt that communication with their doctors was not good; these patients were less likely/comfortable to talk about their PsA symptoms and the impacts of PsA with their doctor. PsA was also more likely to negatively impact these patients’ quality of life. This survey shows that it is important to find ways to improve communication between patients with PsA and their doctors.

Identifiants

pubmed: 34570345
doi: 10.1007/s40744-021-00367-z
pii: 10.1007/s40744-021-00367-z
pmc: PMC8572306
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1741-1758

Informations de copyright

© 2021. The Author(s).

Références

Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957–70.
doi: 10.1056/NEJMra1505557
Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64:ii14–7.
pubmed: 15708927 pmcid: 1766874
Gudu T, Gossec L. Quality of life in psoriatic arthritis. Expert Rev Clin Immunol. 2018;14:405–17.
doi: 10.1080/1744666X.2018.1468252
Gossec L, de Wit M, Kiltz U, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73:1012–9.
doi: 10.1136/annrheumdis-2014-205207
Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700–12.
pubmed: 32434812
Furst DE, Tran M, Sullivan E, et al. Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control. Clin Rheumatol. 2017;36:2045–54.
doi: 10.1007/s10067-017-3578-9
Garrido-Cumbrera M, Hillmann O, Mahapatra R, et al. Improving the management of psoriatic arthritis and axial spondyloarthritis: roundtable discussions with healthcare professionals and patients. Rheumatol Ther. 2017;4:219–31.
doi: 10.1007/s40744-017-0066-2
Coates LC, Orbai A-M, Azevedo VF, et al. Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire. Health Qual Life Outcomes. 2020;18:173.
doi: 10.1186/s12955-020-01422-z
Kish L. Survey sampling. New York: John Wiley and Sons; 1965.
Gibofsky A, Galloway J, Kekow J, et al. Comparison of patient and physician perspectives in the management of rheumatoid arthritis: results from global physician- and patient-based surveys. Health Qual Life Outcomes. 2018;16:211.
doi: 10.1186/s12955-018-1035-3
Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Am J Clin Dermatol. 2016;17:87–97.
doi: 10.1007/s40257-015-0169-x
Diaz JA, Griffith RA, Ng JJ, Reinert SE, Friedmann PD, Moulton AW. Patients’ use of the Internet for medical information. J Gen Intern Med. 2002;17:180–5.
doi: 10.1046/j.1525-1497.2002.10603.x
McMullan M. Patients using the Internet to obtain health information: how this affects the patient-health professional relationship. Patient Educ Couns. 2006;63:24–8.
doi: 10.1016/j.pec.2005.10.006
Zangi HA, Ndosi M, Adams J, et al. EULAR recommendations for patient education for people with inflammatory arthritis. Ann Rheum Dis. 2015;74:954–62.
doi: 10.1136/annrheumdis-2014-206807
Gomez-Reino J, Orbai A-M, Gossec L. The patient’s perspective on psoriatic arthritis: what more can rheumatologists do to optimise disease management? EMJ Rheumatol. 2017;4:50–7.
van Riel P, Alten R, Combe B, et al. Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools. RMD Open. 2016;2:e000302.
doi: 10.1136/rmdopen-2016-000302
Webers C, Beckers E, Boonen A, et al. Development, usability and acceptability of an integrated eHealth system for spondyloarthritis in the Netherlands (SpA-Net). RMD Open. 2019;5:e000860.
pubmed: 31168405 pmcid: 6525608
Kwan YH, Ong WJ, Xiong M, et al. Evaluation of mobile apps targeted at patients with spondyloarthritis for disease monitoring: systematic app search. JMIR Mhealth Uhealth. 2019;7:e14753.
doi: 10.2196/14753
van Eijk-Hustings Y, van Tubergen A, Boström C, et al. EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis. Ann Rheum Dis. 2012;71:13–9.
doi: 10.1136/annrheumdis-2011-200185
Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rhematol. 2019;71:5–32.
doi: 10.1002/art.40726
Tveit KS, Duvetorp A, Østergaard M, et al. Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). J Eur Acad Dermatol Venereol. 2019;33:340–54.
doi: 10.1111/jdv.15252

Auteurs

Laura C Coates (LC)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

Valderilio F Azevedo (VF)

Universidade Federal do Paraná, Curitiba, Brazil.

Joseph C Cappelleri (JC)

Pfizer Inc, Groton, CT, USA.

Jade Moser (J)

The Harris Poll, Rochester, NY, USA.

Lihi Eder (L)

Women's College Research Institute, University of Toronto, Toronto, ON, Canada.

Pascal Richette (P)

Rheumatology Department, Lariboisière Hospital, Lariboisière, University of Paris, Paris, France.

Meng-Yu Weng (MY)

Department of Internal Medicine, Division of Allergy, Immunology, and Rheumatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Ruben Queiro Silva (RQ)

Rheumatology Division, HUCA, Oviedo, Spain.

Amit Garg (A)

Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.

Amar Majjhoo (A)

Shores Rheumatology, St Clair Shores, MI, USA.

Christopher E M Griffiths (CEM)

Dermatology Centre, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester, UK.

Pamela Young (P)

Pfizer Inc, Collegeville, PA, USA.

Samantha Howland (S)

Pfizer Ltd, Walton Oaks, Tadworth, Surrey, KT20 7NS, UK. samantha.howland@pfizer.com.

Classifications MeSH